| 摘要 |
Compounds of formula I and their metabolites are potent mediators of an inflammatory response: (I) where a, b, c, d, e, f, V, W, X, Y, Ra, Ra′, Rb, Rb′, Rc, and Rc′ are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.; |
| 主权项 |
1. A pharmaceutical formulation comprising: an effective amount of a compound having a formula of: wherein: R1 is a heterocyclyl; is an optional double bond; W is —OH, —C(O)H, —C(O), —C(O)Rp, —COOH, —COORp, —Cl, —Br, —I, —CF3, —CN, —SO3, —SO2Rp, —SO3H, —NH3+, —NH2Rp+, —NRpRqRt, —NO2, ═O, ═NRp, ═CF2, or —CHF; each V is, independently —CH or —C—, wherein: V is —CH— when W is —OH, —H, —C(O)H, —C(O), —C(O)Rp, —COON, —COORp, —Cl, —Br, —I, —F, —CF3, —CN, —SO3, —SO2Rp, —SO3H, —NH3+, —NH2Rp+, —NRpRqRt or —NO2; or V is —C— when W is ═O, ═NRp, ═CF2 or ═CHF; Rp and Rq are each, independently, H, (C1-C8) alkyl, aryl, or (C1-C8) haloalkyl; Rt is (C1-C8) alkyl, aryl, or (C1-C8) haloalkyl; Rb and Rb′ are each independently, —H, —OH, —C(O)H, —C(O), —C(O)Rp, —COOH, —COORp, —Cl, —Br, —I, —F, —CF3, —CHF2, —CH2F, —CN, —SO3, —SO2Rp, SO3H, —NH3+, —NH2Rp+, —NRpRqRt or —NO2, wherein:
Rb and Rb′ are not simultaneously non-hydrogen groups;a is an integer between 5 and 15 inclusive, c is an integer from 1 and 15 inclusive, and f is an integer between 5 and 15 inclusive; and a pharmaceutically acceptable carrier. |
